Literature DB >> 25314342

Impact of nutritional iodine optimization on rates of thyroid hypoechogenicity and autoimmune thyroiditis: a cross-sectional, comparative study.

Daniela M C Miranda1, Juliana N Massom, Regina M Catarino, Raimunda T M Santos, Sônia S Toyoda, Marília M S Marone, Eduardo K Tomimori, Osmar Monte.   

Abstract

BACKGROUND: Since several countries have established mandatory food iodine fortification, there has been a decrease in rates of iodine deficiency disorders in parallel with an increase in prevalence of autoimmune thyroid diseases. This study compared the nutritional iodine status and the prevalence of autoimmune thyroiditis and thyroid hypoechogenicity on ultrasound in schoolchildren in São Paulo (Brazil) in two distinct periods of time in which fortified salt had different concentrations of iodine.
METHODS: We conducted a cross-sectional study evaluating 206 children aged 7-14 years and without a history of thyroid disease. Assessments included measurements of thyrotropin (TSH), free thyroxine, antithyroperoxidase (anti-TPO), and antithyroglobulin (anti-TG) antibodies, urinary iodine concentration, and thyroid ultrasound.
RESULTS: Mean urinary iodine concentration was 165.1 μg/L. Eleven children (5.3%) were diagnosed with autoimmune thyroiditis based on at least two of four criteria adopted in our study: positive anti-TPO or anti-TG antibody, hypoechogenicity of the thyroid parenchyma on ultrasound, and a TSH >4.0 μU/mL. Comparing our results with those from a similar study conducted during a period in which concentrations of iodine in the salt were higher (median urinary iodine concentration >300 μg/L), we observed a trend toward a lower prevalence of autoimmune thyroiditis, although no definitive conclusion could be established.
CONCLUSION: The current nutritional iodine status in our cohort was within optimal levels and lower than levels found in 2003. The prevalence of autoimmune thyroiditis seems to be decreasing in parallel with a decrease in iodine intake, although we could not reach a definitive conclusion.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25314342     DOI: 10.1089/thy.2014.0182

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  7 in total

1.  [Hashimoto thyroiditis, therapeutic options and extrathyroidal options - an up-to-date overview].

Authors:  Eva Petnehazy; Wolfgang Buchinger
Journal:  Wien Med Wochenschr       Date:  2019-03-27

2.  Relationship between Gene Polymorphisms and Urine Iodine Levels on Susceptibility to Thyroid Peroxidase Antibody Positivity in the Chinese Population.

Authors:  Bing Han; Chi Chen; Yi Chen; Ningjian Wang; Jie Yu; Jing Cheng; Yingchao Chen; Chunfang Zhu; Yingli Lu
Journal:  Eur Thyroid J       Date:  2020-04-21

Review 3.  Iodoprophylaxis and thyroid autoimmunity: an update.

Authors:  Claudia Teti; Marta Panciroli; Elena Nazzari; Giampaola Pesce; Stefano Mariotti; Antonella Olivieri; Marcello Bagnasco
Journal:  Immunol Res       Date:  2021-04-29       Impact factor: 2.829

4.  Graves Disease in Central Ghana: Clinical Characteristics and Associated Factors.

Authors:  Osei Sarfo-Kantanka; Fred Stephen Sarfo; Eunice Oparebea Ansah; Ishmael Kyei
Journal:  Clin Med Insights Endocrinol Diabetes       Date:  2018-03-21

Review 5.  The Emerging Role of Epigenetics in Autoimmune Thyroid Diseases.

Authors:  Bin Wang; Xiaoqing Shao; Ronghua Song; Donghua Xu; Jin-An Zhang
Journal:  Front Immunol       Date:  2017-04-07       Impact factor: 7.561

6.  Increased Risk of Thyroid Dysfunction Among Patients With Rheumatoid Arthritis.

Authors:  Qian Li; Bin Wang; Kaida Mu; Jing Zhang; Yanping Yang; Wei Yao; Jie Zhu; Jin-An Zhang
Journal:  Front Endocrinol (Lausanne)       Date:  2019-01-11       Impact factor: 5.555

7.  Spot urine iodine levels below the WHO recommendation are not related to impaired thyroid function in healthy children and adolescents.

Authors:  Tillmann Wallborn; Mandy Vogel; Antje Kneuer; Michael Thamm; Katalin Dittrich; Wieland Kiess; Jürgen Kratzsch
Journal:  Eur J Nutr       Date:  2020-05-11       Impact factor: 5.614

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.